Bordon

https://ichgcp.net › clinical-trials-registry
The purpose of the study is to investigate the safety tolerability and pharmacokinetic parameters of 2 dose strengths of donzakimig each administered subcutaneously as a single dose

https://synapse.patsnap.com › drug
The purpose of the study is to investigate the safety tolerability and pharmacokinetic parameters of 2 dose strengths of donzakimig each administered subcutaneously as a single dose

https://www.frontiersin.org › journals › drug-discovery › articles
Currently in early clinical development for moderate to severe AD donzakimig represents a barrier focused complement to galvokimig within UCB s pipeline with particular relevance for

https://ichgcp.net › fr › clinical-trials-registry
Le but de l tude est d tudier l innocuit la tol rabilit et les param tres pharmacocin tiques de 2 dosages de donzakimig chacun administr par voie sous cutan e en dose

https://cdek.pharmacy.purdue.edu › trial
The purpose of the study is to investigate the safety tolerability and pharmacokinetic parameters of 2 dose strengths of donzakimig each administered subcutaneously as a single dose in healthy

https://www.ucb.com › innovation › pipeline
Galvokimig is a multispecific antibody based therapeutic that inhibits IL 13 IL 17A and IL 17F with albumin binding to modulate the serum half life IL 13 IL 17A and IL 17F are key mediators of

https://pryzm.ozmosi.com › product
Discover how you can continue to uncover the competitive landscape and drive strategy UCB is developing ucb 1381 a biologic for treatment of Atopic Dermatitis

https://gsrs.ncats.nih.gov › ginas › app › ui › substances
Immunoglobulin G1 anti human interleukin 22 human Oryctolagus cuniculus 1 chain N terminal fragment fusion protein with peptide linker SGGGGSGGGGS fusion protein with

https://med.agiltrace.com › clinical-trials
Explore studies by the year of their last update The purpose of the study is to investigate the safety tolerability and pharmacokinetic parameters of 2 dose strengths of donzakimig each